Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

BACKGROUND: In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp1...

Descripción completa

Detalles Bibliográficos
Autores principales: Revicki, Dennis A, van den Eertwegh, Alfons JM, Lorigan, Paul, Lebbe, Celeste, Linette, Gerald, Ottensmeier, Christian H, Safikhani, Shima, Messina, Marianne, Hoos, Axel, Wagner, Samuel, Kotapati, Srividya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426458/
https://www.ncbi.nlm.nih.gov/pubmed/22694829
http://dx.doi.org/10.1186/1477-7525-10-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426458/
https://www.ncbi.nlm.nih.gov/pubmed/22694829
http://dx.doi.org/10.1186/1477-7525-10-66

Ejemplares similares